Overview
- The probe centers on allegations that pharmacists and other suspects diverted centrally procured Paxlovid outside official distribution channels in 2023.
- Authorities estimate the illicit scheme resulted in losses of around €2.6 million from the federal COVID-19 medication program.
- Arrest warrants for breach of trust and illegal wholesale trade were executed in Munich, leading to two suspects being remanded in pre-trial detention.
- Investigators seized documents and data carriers during searches in Munich, Regensburg and Bamberg and are currently analyzing the evidence.
- Paxlovid was approved and bulk-procured by the federal government in January 2022 to be dispensed free to patients, with wholesalers and pharmacies receiving a federal expense allowance.